Author

M. Guirola

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Assay:proteomics· 1

Frequent Co-Authors

S. Kourtis· 2 shared S. Sdelci· 2 shared A. Ganez Zapater· 1 shared A. Ganez-Zapater· 1 shared A. Miro Canturri· 1 shared A. Muller· 1 shared C. Cannata· 1 shared D. Cianferoni· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

S. Kourtis

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Comprehensive chromatome profiling identifies metabolic enzymes on chromatin in healthy and cancer cells

S. Kourtis, M. Guirola, N. Pardo-Lorente, R. Ghose, M. Garcia-Cao, A. Ganez-Zapater, S. Haynes, F. Fontaine, A. Muller, S. Sdelci

The paper identifies widespread metabolic enzyme localization on chromatin in healthy and cancer cells, showing tissue-specific abundance and non-canonical roles in DNA damage and repair.

bioRxiv · Dec 6, 2023 · PreprintCancer Biology

The BRD4S-LOXL2-MED1 interaction at the forefront of cell cycle transcriptional control in triple-negative breast cancer

L. Pascual-Reguant, T. V. Tian, D. Datta, D. Cianferoni, S. Kourtis, A. Ganez Zapater, C. Cannata, Q. Serra Camprubi, L. Espinar, M. Guirola, J. Querol, A. Miro Canturri, J. Arribas, L. Serrano, S. Peiro, S. Sdelci

This study shows that inhibiting LOXL2 and BRD4 together reduces triple-negative breast cancer proliferation by disrupting the BRD4S-LOXL2-MED1 interaction that controls cell cycle gene expression.

bioRxiv · May 27, 2022 · PreprintCancer Biology